Burosumab
Burosumab (KRN23) is a human monoclonal antibody targeting fibroblast growth factor 23 (FGF23) for the treatment of cutaneous-skeletal hypophosphatemic syndrome (CSHS) and tumor-induced osteochondrosis.
Product Specifications
CAS Number
1610833-03-8
Stability
≥ 2 years
Purity
>98% (HPLC)
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
Others
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
orb1785199-01 20 µg
Recombinant Sendai virus Fusion glycoprotein F0 (F), partial
Sign In for Pricing
View Details